Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Centessa Pharmaceuticals plc (CNTA)

160 + Investors. Track Smart Money conviction in CNTA. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +14
Streak
3Q ▲
Buyers last Q
54%

Smart Money Signals — CNTA

Based on 160 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added CNTA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
160 hedge funds hold CNTA right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +22% more funds vs a year ago

fund count last 6Q
+29 new funds entered over the past year (+22% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 54% buying

100 buying84 selling
Last quarter: 100 funds bought or added vs 84 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+7 vs last Q)

new funds entering per quarter
Funds opening a new CNTA position: 19 → 26 → 41 → 48. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
📌

Mixed — 34% long-term, 46% new

■ 34% conviction (2yr+) ■ 21% medium ■ 46% new
Of the 160 current holders: 54 (34%) held >2 years, 33 held 1–2 years, and 73 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💰

Value +68% but shares only +3% — price-driven

Value
+68%
Shares
+3%
Last quarter: the total dollar value of institutional holdings rose +68%, but actual share count only changed +3%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

34 → 19 → 26 → 41 → 48 new funds/Q
New funds entering each quarter: 19 → 26 → 41 → 48. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
📊

Mixed cohorts — 34% veterans, 49% new entrants

■ 34% veterans ■ 18% 1-2yr ■ 49% new
Of 173 current holders: 58 (34%) held 2+ years, 31 held 1–2 years, 84 (49%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
📋

Smaller funds dominant — 18% AUM from top-100

18% from top-100 AUM funds
30 of 159 holders rank in the top 100 by AUM, but together hold only 18% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
4.6
out of 10
Moderate Exit Risk
Exit risk score 4.6/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CNTA

In 2026 Q1, 100 hedge funds were net buyers of CNTA (48 opened a new position, 52 added to an existing one), while 84 reduced or exited (50 trimmed, 34 sold completely) — a 54% buyer ratio, indicating a slight buying edge. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. Net fund flow last quarter: +14 funds (more new holders than closures). Total institutional holders: 160.

Hedge Fund Ownership: CNTA

How many hedge funds hold CNTA — quarterly history vs. share price
Quarterly hedge fund ownership of CNTA vs. share price

Market Analysis: CNTA

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CNTA

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Centessa Pharmaceuticals plc (CNTA) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CNTA has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 75d ago
CNTA
+0.0%
XLV
+4.9%

CNTA outperformed XLV by -4.9% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 30d ago
CNTA
+0.3%
XLV
+6.0%

Since the filing became public, CNTA outperformed XLV by -5.7% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

15 top-rated funds 9 high-conviction
Consensus
5.2
/ 10
breadth
×
Elite
5.8
/ 10
conviction
Hedge Fund Positioning: CNTA
160 + Investors

Track Smart Money conviction in CNTA. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 160 146 9.59%
13F Shares 149M 144M 3.37%
Total Value $5.91B $3.51B 68.18%
New Positions 48 41 +7
Increased Positions 50 47 +3
Closed Positions 34 23 +11
Reduced Positions 45 47 -2
Total Calls 8 7 14.29%
Total Puts 6 4 50.0%
PUT/CALL Ratio 0.75 0.57 Neutral

Statistics: CNTA

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

160 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CNTA. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CNTA holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Index Venture Life Associates VI Ltd 100.00% 9,961,789 $395.7M
2 Medicxi Ventures Management (Jersey) Ltd 80.76% 19,963,157 $792.9M
3 Foresite Capital Management VI LLC 11.77% 1,364,019 $54.2M
4 EcoR1 Capital, LLC 10.11% 6,000,000 $238.3M
5 5AM Venture Management, LLC 6.41% 580,945 $23.1M
6 First Light Asset Management, LLC 5.56% 1,560,991 $62.0M
7 TCG Crossover Management, LLC 4.87% 4,286,480 $170.3M
8 Spruce Street Capital LP 4.68% 489,849 $19.5M
9 Avoro Capital Advisors LLC 4.47% 11,430,455 $454.0M
10 Logos Global Management LP 4.21% 2,125,000 $84.4M
11 Perceptive Advisors LLC 4.09% 5,258,903 $208.9M
12 HighMark Wealth Management LLC 3.83% 236,785 $9.4M
13 Octagon Capital Advisors LP 3.30% 750,000 $29.8M
14 Paradigm Biocapital Advisors LP 2.90% 3,574,048 $142.0M
15 Affinity Asset Advisors, LLC 2.87% 1,400,000 $55.6M
16 Braidwell LP 2.63% 1,986,768 $78.9M
17 General Atlantic, L.P. 2.50% 1,354,830 $53.8M
18 Bain Capital Life Sciences Investors, LLC 2.27% 635,000 $25.2M
19 Cormorant Asset Management, LP 2.09% 1,050,000 $41.7M
20 Deep Track Capital, LP 2.05% 3,158,041 $125.4M
21 Alpine Associates Management INC. 2.03% 865,500 $34.4M
22 PFM Health Sciences, LP 1.91% 528,224 $21.0M
23 Silverarc Capital Management, LLC 1.89% 466,345 $18.5M
24 Pentwater Capital Management LP 1.68% 8,170,000 $324.5M
25 Harvest Management LLC 1.54% 80,000 $3.2M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Centessa Pharmaceuticals plc (CNTA)

What does the Smart Money Trend signal show for CNTA?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added CNTA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CNTA?

Slight buying edge — 54% buying: Last quarter: 100 funds bought or added vs 84 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for CNTA holders?

Smaller funds dominant — 18% AUM from top-100: 30 of 159 holders rank in the top 100 by AUM, but together hold only 18% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held CNTA?

Mixed — 34% long-term, 46% new: Of the 160 current holders: 54 (34%) held >2 years, 33 held 1–2 years, and 73 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Centessa Pharmaceuticals plc (CNTA) following the 2026 Q1 hedge fund 13F filings?

As of today, CNTA has moved +0.3% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -5.7%. Since the quarter end (March 31, 2026), CNTA has gained +0.0% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →